Amendments to the Claims

1. (Original) A compound represented by the formula (I)



(I)

wherein R^1 and R^2 are each a lower alkyl group optionally having substituents, or a salt thereof.

2. (Original) The compound of claim 1, wherein R^2 is a lower alkyl group substituted by an aromatic hydrocarbon group, or a salt thereof.

3. (Original) A compound represented by the formula (I)



(I)

wherein R^1 is a lower alkyl group optionally having substituents, R^2 is a lower alkyl group, or a salt thereof.

4. (Original) The compound of claim 3, wherein R^2 is a lower alkyl group having 3 or 4 carbon atoms, or a salt thereof.

5. (Original) The compound of claim 4, wherein the lower alkyl group is isopropyl or isobutyl, or a salt thereof.

6. (Currently amended) The compound of ~~any of claims 1 to 5~~ claim 1, wherein R^1 is a lower alkyl group having substituent(s), or a salt thereof.

7. (Original) The compound of claim 6, wherein the substituent(s) that the lower alkyl group has is an aromatic hydrocarbon group optionally having substituents, or a salt thereof.

8. (Original) The compound of claim 7, wherein the aromatic hydrocarbon group is an aromatic hydrocarbon group substituted by a group selected from the group consisting of a hydroxy group, a lower alkoxy group, a cyclohexylmethoxy group, a halogen atom and a phenyl group.

9. (Currently amended) The compound of claim 7 ~~or 8~~, wherein the aromatic hydrocarbon group is a phenyl group or 2-naphthyl group.

10. (Original) (2S,5S)-5-Benzyl-6-hydroxy-2-(2-methylpropyl)-3-morpholinone.

11-13. (Cancelled)

14. (Original) A pharmaceutical composition comprising a compound represented by the formula (I)



(I)

wherein R^1 and R^2 are each a lower alkyl group optionally having substituents, or a salt thereof and a pharmaceutically acceptable carrier.

15. (Original) The pharmaceutical composition of claim 14, which is a calpain inhibitor.

16. (Original) A method for treating a disease in which calpain is involved, which comprises administering an effective amount of a compound represented by the formula (I)



(I)

wherein R^1 and R^2 are each a lower alkyl group optionally having substituents, or a salt thereof, to a mammal in need of the treatment.

17. (Cancelled)

18. (New) The compound of claim 3, wherein R^1 is a lower alkyl group having substituent(s), or a salt thereof.

19. (New) The compound of claim 18, wherein the substituent(s) that the lower alkyl group has is an aromatic hydrocarbon group optionally having substituents, or a salt thereof.

20. (New) The compound of claim 19, wherein the aromatic hydrocarbon group is an aromatic hydrocarbon group substituted by a group selected from the group consisting of a hydroxy group, a lower alkoxy group, a cyclohexylmethoxy group, a halogen atom and a phenyl group.

21. (New) The compound of claim 20, wherein the aromatic hydrocarbon group is a phenyl group or 2-naphthyl group.